Afterwards, this dose was tested in a phase 2, single-arm trial of endocrine-resistant, ER-positive/HER2-low BC patients, who had experienced disease progression while on a cyclin-dependent kinase 4 and 6 inhibitor (CDK4/6i) [26,57]. The gene discussed is ERBB2; the disease is breast cancer.